Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

Andriani, Alessandro; Miedico, A.; Tedeschi, L.; Patti, Caterina; Raimondo, Francesco Di; Leone, Monica; Schinocca, Luciana; Romanelli, Antonella; Bonanno, George A.; Linea, C.; Giustini, Marco; Hassan, Cesare; Cottone, Mario; Zullo, Angelo

doi:10.1016/j.dld.2008.09.009

Cited by 37 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 3-year survival rate was 90.3% and the 5-year survival rate was 76.2%. This is consistent with previous studies conducted in different countries (3,5,6). Recently, it has been demonstrated that patients with H. pylori-negative gastric MALT lymphomas achieve CR following exclusive anti-H. pylori treatment (30).…”

Section: Discussionsupporting

confidence: 81%

“…There have been few reports investigating the long-term effect of H. pylori eradication therapy. Previous studies have demonstrated that H. pylori eradication leads to the regression of early stage lymphoma (6)(7)(8). However, the traditional strategies used to treat gastric MALT lymphoma are surgery and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…disease confined to the stomach with or without involvement of the paragastric lymph nodes and with no distant lymph node involvement) who were admitted to Tianjin Medical University General Hospital (Tianjin, China) were enrolled in the present study between January 2000 and January 2013. All patients had stage I1E (confined to the stomach) or II1E (involvement of paragastric lymph nodes) MALT lymphoma according to the Ann Arbor classification system modified by Musshoff (6,18,19). H. pylori status was determined using the rapid urease test, Giemsa staining or the 13 C urea breath test (7).…”

Section: Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical manifestations and epigenetic mechanisms of gastric mucosa associated lymphoid tissue lymphoma and long‑term follow‑up following Helicobacterï¿½pylori eradication

Song

Jiang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. The current study aimed to summarize the clinical manifestations and identify the epigenetic mechanisms of gastric mucosa associated lymphoid tissue (MALT) lymphoma, as well as evaluate the long-term effects of Helicobacter pylori (H. pylori) eradication. A total of 122 patients with marginal zone B-cell lymphoma of primary gastric MALT lymphoma were enrolled in the present study. The clinical manifestations of gastric MALT lymphoma, including symptoms, H. pylori state and endoscopic type, were summarized. The response to therapy was evaluated in patients that underwent H. pylori eradication. Survival analysis was estimated using the Kaplan-Meier method. The expression of microRNA-383 (miR-383) in tumor tissues and cell lines was determined using reverse transcription quantitative polymerase chain reaction. Furthermore, bioinformatic analyses, luciferase reporter assays. and western blot analysis identified zinc finger E-box binding homeobox 2 (ZEB2) as a direct target gene of miR-383. An MTT assay was used to examine the function of miR-383 and ZEB2 in MALT lymphoma. The clinical symptoms of patients with gastric MALT lymphoma were non-specific and included epigastric pain, abdominal discomfort and bleeding. The majority of endoscopic types were classified as ulcer, erosion and mucosa edema. The H. pylori infection rate was 79.5% (97/122) and a total of 47 patients underwent eradication therapy. Lymphoma remission was achieved in 93.6% (44/47) of patients and complete remission (CR) was achieved in 74.4% (35/47). The median follow-up time was 38 months (range, 10-132 months) and the median time taken to achieve CR was 4 months (range, 3-7 months). The estimated 3-year survival rate was 90.3% and the 5-year survival rate was 76.2%. Therefore, it was determined that patients with stage I or II gastric MALT lymphoma are able to undergo H. pylori eradication as a first-line treatment and that the survival rate of patients undergoing this treatment is high. Furthermore, it was determined that the mechanism by which miR-383 and ZEB2 contribute to MALT lymphoma progression is by the targeting of ZEB2 by miR-383, which inhibits the proliferation of cancer cells.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical manifestations and epigenetic mechanisms of gastric mucosa associated lymphoid tissue lymphoma and long‑term follow‑up following Helicobacterï¿½pylori eradication

Song

Jiang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Table 2 indicates 9 retrospective studies 12, 15, 20, 21, 22, 26, 27, 28, 29 of 49‐376 patients. In total, CR was achieved in 852 of 1,055 patients (80.8%) including patients with successful and unsuccessful H. pylori eradication.…”

Section: Discussionmentioning

confidence: 99%

Anti‐Helicobacter pylori therapy in localized gastric mucosa‐associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan

et al. 2018

View full text Add to dashboard Cite

Background Helicobacter pylori eradication therapy was approved in Japan for the first‐line, standard treatment of H. pylori‐positive gastric mucosa‐associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small‐scale single‐center studies have been reported, a prospective, large‐scale, nationwide, multicenter study has not been reported from Japan.Materials and MethodsWe conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole‐based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice‐based clinical trial. A total of 108 H. pylori‐positive patients with stage I/II 1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS).Results CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0‐44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4‐53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow‐up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma.ConclusionsRabeprazole‐based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice‐based, multicenter study.

show abstract

“…81 Stage I tumours extending beyond the submucosa are better treated with chemotherapy, radiation or a combination of both, yielding remission rates of up to 90%. 82 Stage II or higher GL tumours can be treated with subtotal gastrectomy (open or laparoscopic) combined with removal of any nodular metastases.…”

Section: Surgical Treatment and Molecular Prognostic Markersmentioning

confidence: 99%

Review of the molecular profile and modern prognostic markers for gastric lymphoma: How do they affect clinical practice?

et al. 2012

View full text Add to dashboard Cite

Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

Cited by 37 publications

References 41 publications

Clinical manifestations and epigenetic mechanisms of gastric mucosa associated lymphoid tissue lymphoma and long‑term follow‑up following Helicobacterï¿½pylori eradication

Clinical manifestations and epigenetic mechanisms of gastric mucosa associated lymphoid tissue lymphoma and long‑term follow‑up following Helicobacterï¿½pylori eradication

Anti‐Helicobacter pylori therapy in localized gastric mucosa‐associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan

Review of the molecular profile and modern prognostic markers for gastric lymphoma: How do they affect clinical practice?

Contact Info

Product

Resources

About